文拉法辛合并利培酮治疗躯体化障碍对照研究  

A study of risperidone combining with venlafaxine in the treatment of somatization disorder

作　　者：陈红生[1] 刘志美[1] 王泉英[1] 

机构地区：[1]山东省滨州市人民医院精神卫生中心,山东滨州256613

出　　处：《中国民康医学》2008年第11期1125-1126,共2页Medical Journal of Chinese People’s Health

摘　　要：目的:探讨文拉法辛合并利培酮治疗躯体化障碍的疗效及安全性。方法:将符合CCMD-3诊断标准的60例躯体化障碍患者随机分为治疗组(n=30)和对照组(n=30),治疗组给予文拉法辛合并利培酮治疗,对照组只给予文拉法辛治疗。应用汉密尔顿抑郁量表(HAMD),汉密尔顿焦虑量表(HAMA)及副反应量表(TESS)评定疗效及不良反应,疗程6周。结果:在治疗2、4、6周末,治疗组疗效优于对照组,两组疗效比较具有显著性统计学意义(P<0.05)。结论:文拉法辛合并利培酮治疗躯体化障碍效果优于单用文拉法辛。Objective;To explore the efficacy and safety of risperidone combining with venlafaxine in the treatment of somatization disorder. Methods ： A total of 60 outpatients who met the criteria of CCMD - 3 for somatization disorder were assigned to therapeutic group（ n = 30 ）and control group （n = 30 ）for the treatment of 6 weeks. Therapeutic group was given venlafaxine in addition to risperidone, and control group was venlafaxine alone. The clinical effect was assessed with HAMD and HAMA at the end of 2nd, 4th and 6th week. The adverse reaction was evaluated by TESS. Results： The therapeutic efficacy in venlafaxine plus risperidone group was significantly higher than that in control group. Conclusions ： Venlafaxine plus risperidone has better effect in the treatment of somatization disorder than venlafaxine only.

关 键 词：文拉法辛 利培酮 躯体化障碍 

分 类 号：R749.2[医药卫生—神经病学与精神病学]